Lauris v. Novartis AG, 1-16-cv-00393-SEH. (2018)
Court: District Court, E.D. California
Number: infdco20180706532
Visitors: 5
Filed: Jun. 27, 2018
Latest Update: Jun. 27, 2018
Summary: ORDER SAM E. HADDON , District Judge . Defendant Novartis Pharmaceuticals Corporation's Filing of Supplemental Trial Exhibit 1 regarding DX 821, filed on April 9, 2018, fails to inform the Court whether DX 821 is to be designated as a "will-offer" or as a "may-offer" exhibit. ORDERED: Defendant Novartis Pharmaceuticals shall file a notice with the Court identifying DX 821 as either a will-offer exhibit or a may-offer exhibit on or before 4:45 pm (MT) on June 29, 2018. FootNotes 1. Do
Summary: ORDER SAM E. HADDON , District Judge . Defendant Novartis Pharmaceuticals Corporation's Filing of Supplemental Trial Exhibit 1 regarding DX 821, filed on April 9, 2018, fails to inform the Court whether DX 821 is to be designated as a "will-offer" or as a "may-offer" exhibit. ORDERED: Defendant Novartis Pharmaceuticals shall file a notice with the Court identifying DX 821 as either a will-offer exhibit or a may-offer exhibit on or before 4:45 pm (MT) on June 29, 2018. FootNotes 1. Doc..
More
ORDER
SAM E. HADDON, District Judge.
Defendant Novartis Pharmaceuticals Corporation's Filing of Supplemental Trial Exhibit1 regarding DX 821, filed on April 9, 2018, fails to inform the Court whether DX 821 is to be designated as a "will-offer" or as a "may-offer" exhibit.
ORDERED:
Defendant Novartis Pharmaceuticals shall file a notice with the Court identifying DX 821 as either a will-offer exhibit or a may-offer exhibit on or before 4:45 pm (MT) on June 29, 2018.
FootNotes
1. Doc. 396.
Source: Leagle
